Sangamo Therapeutics, Inc. (SGMOQ)
0.1102
-0.03
(-21.79%)
USD |
OTCM |
Oct 16, 16:00
Sangamo Therapeutics Free Cash Flow : -90.46M for March 31, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2026 | -90.46M |
| December 31, 2025 | -97.31M |
| September 30, 2025 | -76.40M |
| June 30, 2025 | -36.19M |
| March 31, 2025 | -44.89M |
| December 31, 2024 | -67.41M |
| September 30, 2024 | -117.11M |
| June 30, 2024 | -178.79M |
| March 31, 2024 | -218.16M |
| December 31, 2023 | -246.00M |
| September 30, 2023 | -257.31M |
| June 30, 2023 | -265.30M |
| March 31, 2023 | -258.48M |
| December 31, 2022 | -243.80M |
| September 30, 2022 | -234.85M |
| June 30, 2022 | -241.44M |
| March 31, 2022 | -241.84M |
| December 31, 2021 | -256.53M |
| September 30, 2021 | -209.26M |
| June 30, 2021 | -115.58M |
| March 31, 2021 | 101.33M |
| December 31, 2020 | 155.16M |
| September 30, 2020 | 135.87M |
| June 30, 2020 | 63.80M |
| March 31, 2020 | -136.65M |
| Date | Value |
|---|---|
| December 31, 2019 | -165.08M |
| September 30, 2019 | -205.08M |
| June 30, 2019 | -198.92M |
| March 31, 2019 | -36.26M |
| December 31, 2018 | -5.913M |
| September 30, 2018 | 43.96M |
| June 30, 2018 | 64.43M |
| March 31, 2018 | 0.224M |
| December 31, 2017 | 7.428M |
| September 30, 2017 | 12.62M |
| June 30, 2017 | 11.81M |
| March 31, 2017 | -59.55M |
| December 31, 2016 | -66.62M |
| September 30, 2016 | -63.28M |
| June 30, 2016 | -60.52M |
| March 31, 2016 | -53.27M |
| December 31, 2015 | -36.13M |
| September 30, 2015 | -29.72M |
| June 30, 2015 | -21.14M |
| March 31, 2015 | -21.03M |
| December 31, 2014 | -6.296M |
| September 30, 2014 | -4.896M |
| June 30, 2014 | -3.594M |
| March 31, 2014 | -0.255M |
| December 31, 2013 | -19.59M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sarepta Therapeutics, Inc. | 58.34M |
| Anixa Biosciences, Inc. | -7.376M |
| Vicapsys Life Sciences, Inc. | -0.1292M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -19.28M |
| Cash from Investing (Quarterly) | -0.013M |
| Cash from Financing (Quarterly) | 26.70M |
| Free Cash Flow Per Share (Quarterly) | -0.0495 |
| Free Cash Flow to Equity (Quarterly) | -11.83M |
| Free Cash Flow to Firm (Quarterly) | -19.30M |
| Free Cash Flow Yield | -254.8% |